Background: Nebivolol is a new beta-adrenergic blocking agent which has been shown to cause vasodilation when infused in the forearm vascular bed both in normotensive and in hypertensive subjects, and this effect is probably mediated by the activation of the L-arginine/NO pathway.
The data from the Enalapril Pediatric Hypertension Study were examined to compare the estimated standard deviation (SD) for sitting systolic (SiSBP) and diastolic (SiDBP) blood pressures (BP) of the hypertensive children included in the study with estimates from the general pediatric population. The best available estimate of (BP) variability in children was published in the Second Task Force Report (Pediatrics, 1987, 79:1-25) . For children aged 6-16 years, the SD for SiSBP ranged from 10.0 to 12.9 mmHg (based on single clinic BP measurement). In children aged 13-16 years, the SD for SiDBP using the 5th Korotkoff sound (K5) ranged from 10.5 to 12.7 mmHg (SBPM). Values for K5 were not published for children Յ 12 years of age. In Period 1 of the enalapril study, patients were randomized to 1 of 3 enalapril treatments q.d. for 14 days: 0.625/1.25 mg, 2.5/5 mg, or 20/40 mg (based on weight). In Period 2, patients either continued their current study regimen or were switched to placebo for up to 2 weeks or when their BP returned to baseline, whichever came first. For Period 1, the power calculation was based on a desired difference (␦) of 5 mmHg in the mean trough SiDBP between high-and low-dose groups. For Period 2, the desired difference (␦) in the mean trough SiDBP between active treatment and placebo groups was also set at 5 mmHg. All BP readings were the mean of 3 measurements. Planned and actual values for each period are shown: Actual SDs were obtained from pooled SDs for each treatment arm in both Periods. The SD for SiDBP in hypertensive children, under the criteria, was less than expected from previously published results. SD results for SiSBP were similar to previously published results in a non-selected population. Accordingly, given similar inclusion and exclusion criteria, the power analysis for studies using SiDBP as the primary outcome measure may employ slightly lower values for SD than previously published in the literature when using the mean of 3 BP measurements. This study was to evaluate the antihypertensive efficacy of amlodipine in patients with severe hypertension. After being weaned from antihypertensive therapy, patients with severe hypertension (average sitting diastolic blood pressure [ASDBP] of 110 to 120 mm Hg inclusive) entered a 1-week placebo run-in phase (Phase I) before starting therapy with amlodipine 5 mg/day in an up to 19-week titration phase (Phase II), during which treatment was adjusted according to predefined ASDBP targets. If targets were not met by treatment with 5 mg/day amlodipine, the dose was increased to 10 mg/day; if targets were still not met, chlorthalidone 15 mg/day was added to the amlodipine treatment regimen. Patients entered a 4-week maintenance phase (Phase III) when they reached goal ASDBP (Ͻ90 mm Hg on 2 consecutive visits); patients not meeting goal after 19-weeks titration or after 4 weeks of amlodipine/ chlorthalidone combination were discontinued from the study. During Phase III, patients were maintained on amlodipine monotherapy or amlodipine/chlorthalidone. Office BP was determined at weekly or biweekly intervals throughout the study; 24-hour ambulatory BP monitoring was performed at the end of the Phase I and Phase III. A total of 101 patients (70 males, 31 females) aged 34 to 75 years started Phase II. At the end of maintenance, 31% (31/101) of the patients remained on amlodipine monotherapy and 58.1% of them were at goal BP or had a reduction in ASDBP of 20 mm Hg or more from baseline. Comparatively, 69% (70/101) of the patients required both amlodipine and chlorthalidone during Phase II, and 55.1% of them were at goal BP or had a reduction in ASDBP of 20 mm Hg or more from baseline. All office BP measurements were statistically significantly (PϽ0.001) decreased from baseline.
109A AJH-April 2001-VOL. 14, NO. 4, PART Omitted data is due to insufficient number of patients. We did not analyze the data for specific types of CCBs. The data showed that at matching SBP quintiles elderly African-Americans had a lower relative risk of death than their white counterparts while receiving CCBs. This data suggests that CCBs were effective in decreasing two year mortality in elderly African-Americans, particularly those with the highest level of SBP.
Key Words: calcium channel blockers, elderly, black americans The nephroprotective action of different antihypertensive drugs has not yet been completely elucidated. This study was aimed at comparing the effects of antihypertensive drugs on renal hemodynamics during adrenergic activation induced by mental stress (MS), a stimulus that induces renal vasoconstriction. The renal hemodynamic profile was assessed in 15 patients (pts.) with essential hypertension (EH), aged 48-66 yrs. Each pt. was assessed twice: after two weeks of pharmacological wash-out and other two weeks of treatment with trandolapril (T, 4mg, nϭ5), verapamil (V, 280mg, nϭ5) or both (T 2mg ϩ V 180mg, nϭ5). Each assessment consisted of four 30-minute experimental periods (baseline, MS, recovery I and II). All three antihypertensive regimens normalized the blood pressure (BP) similarly, and MS increased BP by a similar extent before and after each treatment. Conversely, the renal responses to MS were quite different. Before treatment, the rise in BP induced by MS was not associated with the physiological increase in renal vascular resistance, and no change occurred in effective renal plasma flow (ERPF, from PAI clearance) and in glomerular filtration rate (GFR, from inulin clearance). After antihypertensive treatment, the renal vascular response to MS was modified differently by the three drugs. In pts. treated with T (nϭ5) the renal vasoconstriction occurred only during the MS-related BP rise, while those receiving V (nϭ5) or the combination (nϭ5) had a more prolonged vasoconstriction. Therefore, only high doses of T restored the physiological renal hemodynamic response to adrenergic activation. In conclusion, the kidney of pts. with EH is unable to react to sympathetic activation. A short-term antihypertensive treatments can modify the pathological renal response of EH, but only high doses of T can revert renal reactivity back to normal. We reviewed data from the Cooperative Cardiovascular Project (CCP). This project is a database of one of the largest number of elderly patients with an acute myocardial infarction (AMI). Pulse pressure data was analyzed by quartile to determine the impact of Calcium channel blockers (CCBs) on survival of elderly patients. Data was not analyzed as to specific types of CCBs. 110A AJH-April 2001-VOL. 14, NO. 4 , PART 2 POSTERS: Antihypertensive Drugs
